Efficiency of incorporation and chain termination determines the inhibition potency of 2′-modified nucleotide analogs against hepatitis C virus polymerase

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3636-3645

  Fung, Amy ^a   Jin, Zhinan ^a   Dyatkina, Natalia ^a   Wang, Guangyi ^a   Beigelman, Leo ^a   Deval, Jerome ^a  

^a Alios BioPharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' ARA URIDINE TRIPHOSPHATE; 2' C METHYLURIDINE TRIPHOSPHATE; 2' FLUORO URIDINE TRIPHOSPHATE; 2' N 3 URIDINE TRIPHOSPHATE; 2' NH 2 URIDINE TRIPHOSPHATE; 3' DEXTRO URIDINE TRIPHOSPHATE; ANTIVIRUS AGENT; BETA DEXTRO 2' DEOXY 2' ALPHA FLUORO 2' BETA C METHYLURIDINE TRIPHOSPHATE; NUCLEOSIDE TRIPHOSPHATE; RIBOSE; RNA DIRECTED RNA POLYMERASE INHIBITOR; SOFOSBUVIR; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE; ENZYME INHIBITOR; GUANOSINE TRIPHOSPHATE; RNA DIRECTED RNA POLYMERASE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ENZYME SUBSTRATE; HEPATITIS C VIRUS; IC 50; NONHUMAN; PRIORITY JOURNAL; RNA SYNTHESIS; RNA TRANSLATION; STEADY STATE; ALGORITHM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; HEPACIVIRUS; HUMAN; KINETICS; METABOLISM;

ALGORITHMS; ANTIVIRAL AGENTS; ENZYME INHIBITORS; GUANOSINE TRIPHOSPHATE; HEPACIVIRUS; HUMANS; KINETICS; RNA REPLICASE; URIDINE TRIPHOSPHATE;

EID: 84903177093     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02666-14     Document Type: Article

References (37)

1. Moradpour D, Penin F, Rice CM. 2007. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5:453-463. http://dx.doi.org/10.1038/nrmicro1645. (Pubitemid 46780082)
2. Alter HJ, Houghton M. 2000. Clinical medical research award. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat. Med. 6:1082-1086. http://dx.doi.org/10.1038/80394.
3. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973. http://dx.doi.org/10.1002/ hep.20819. (Pubitemid 41401136)
4. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. 1999. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6:937-943. http://dx.doi.org/10.1038/13305. (Pubitemid 29463307)
5. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7:1417-1426. http://dx.doi.org/10.1016/S0969-2126(00)80031-3. (Pubitemid 29529882)
6. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 96:13034-13039. http://dx.doi.org/10.1073/pnas.96.23.13034.
7. Caillet-Saguy C, Simister PC, Bressanelli S. 2011. An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors. J. Mol. Biol. 414:370-384. http://dx.doi.org/10.1016/j.jmb.2011.10.001.
8. Scrima N, Caillet-Saguy C, Ventura M, Harrus D, Astier-Gin T, Bressanelli S. 2012. Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405. J. Virol. 86:7107-7117. http://dx.doi.org/10.1128/JVI.00459-12.
9. Jin Z, Leveque V, Ma H, Johnson KA, Klumpp K. 2012. Assembly, purification, and pre-steady-state kinetic analysis of active RNA-dependent RNA polymerase elongation complex. J. Biol. Chem. 287:10674-10683. http://dx.doi.org/10.1074/jbc.M111.325530.
10. Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, Svarovskaia ES, Mo H, Kouyos RD, Gotte M. 2011. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc. Natl. Acad. Sci. U. S. A. 108:20509-20513. http://dx.doi.org/10.1073/pnas.1105797108.
11. Lohmann V, Roos A, Korner F, Koch JO, Bartenschlager R. 1998. Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology 249:108-118. http://dx.doi.org/10.1006/viro.1998.9311. (Pubitemid 28430912)
12. Tomei L, Vitale RL, Incitti I, Serafini S, Altamura S, Vitelli A, De Francesco R. 2000. Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J. Gen. Virol. 81:759-767. (Pubitemid 30105507)
13. Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, Bhat B, Hall D, Simcoe AL, LaFemina R, Rutkowski CA, Wolanski B, Yang Z, Migliaccio G, De Francesco R, Kuo LC, MacCoss M, Olsen DB. 2003. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278:11979-11984. http://dx.doi.org/10.1074/jbc.M210914200. (Pubitemid 36800172)
14. Klumpp K, Leveque V, Le Pogam S, Ma H, Jiang WR, Kang H, Granycome C, Singer M, Laxton C, Hang JQ, Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N, Martin JA, Devos R, Najera I. 2006. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 281:3793-3799. http://dx.doi.org/10.1074/jbc.M510195200. (Pubitemid 43847803)
15. Ma H, Jiang WR, Robledo N, Leveque V, Ali S, Lara-Jaime T, Masjedizadeh M, Smith DB, Cammack N, Klumpp K, Symons J. 2007. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J. Biol. Chem. 282:29812-29820. http://dx.doi.org/10.1074/jbc.M705274200. (Pubitemid 350035263)
16. Murakami E, Bao H, Ramesh M, McBrayer TR, Whitaker T, Micolochick Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ, Furman PA. 2007. Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob. Agents Chemother. 51:503-509. http://dx.doi.org/10.1128/AAC.00400-06. (Pubitemid 46185267)
17. Murakami E, Niu C, Bao H, Micolochick Steuer HM, Whitaker T, Nachman T, Sofia MA, Wang P, Otto MJ, Furman PA. 2008. The mechanism of action of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-D-2′-deoxy-2′-fluoro- 2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 52:458-464. http://dx.doi.org/10.1128/AAC.01184-07. (Pubitemid 351170814)
18. Reddy PG, Bao D, Chang W, Chun BK, Du J, Nagarathnam D, Rachakonda S, Ross BS, Zhang HR, Bansal S, Espiritu CL, Keilman M, Lam AM, Niu C, Steuer HM, Furman PA, Otto MJ, Sofia MJ. 2010. 2′-Deoxy-2′-alpha-fluoro- 2′-beta-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938. Bioorg. Med. Chem. Lett. 20:7376-7380. http://dx.doi.org/10.1016/j.bmcl.2010.10.035.
19. Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, Granycome C, Hang J, Hobbs CJ, Jiang WR, Laxton C, Le Pogam S, Leveque V, Ma H, Maile G, Merrett JH, Pichota A, Sarma K, Smith M, Swallow S, Symons J, Vesey D, Najera I, Cammack N. 2007. Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg. Med. Chem. Lett. 17:2570-2576. http://dx.doi.org/10.1016/j.bmcl.2007.02.004. (Pubitemid 46509839)
20. Standring DN, Benzaria S, Bergelson S, Bichko V, Bridges E, Chung RT, Cretton-Scott E, Gosselin G, La CollaP, Lanford R, Moussa A, Pan-Zhou X, Pierra C, Qu L, Sommadossi JP, Storer R, Tausek M, Wright T. 2003. NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee. J. Hepatol. 38(Suppl 2):1-3. http://dx.doi.org/10. 1016/S0168-8278(03)80421-X.
21. Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie MY, Schinazi RF, Morrey JD, Julander JL, Furman PA, Otto MJ. 2006. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir. Chem. Chemother. 17:79-87.
22. Tomassini JE, Getty K, Stahlhut MW, Shim S, Bhat B, Eldrup AB, Prakash TP, Carroll SS, Flores O, MacCoss M, McMasters DR, Migliaccio G, Olsen DB. 2005. Inhibitory effect of 2′-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells. Antimicrob. Agents Chemother. 49:2050-2058. http://dx.doi.org/10.1128/AAC.49.5.2050-2058. 2005. (Pubitemid 40631624)
23. Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA. 2010. Discovery of a beta-D-2′-deoxy-2′- alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53:7202-7218. http://dx.doi.org/10.1021/jm100863x.
24. Mosley RT, Edwards TE, Murakami E, Lam AM, Grice RL, Du J, Sofia MJ, Furman PA, Otto MJ. 2012. Structure of hepatitis C virus polymerase in complex with primer-template RNA. J. Virol. 86:6503-6511. http://dx.doi.org/10.1128/JVI. 00386-12.
25. Jin Z, Leveque V, Ma H, Johnson KA, Klumpp K. 2013. NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 110:E348-E357. http://dx.doi.org/10.1073/pnas. 1214924110.
26. Johnson KA, Simpson ZB, Blom T. 2009. Global kinetic explorer: a new computer program for dynamic simulation and fitting of kinetic data. Anal. Biochem. 387:20-29. http://dx.doi.org/10.1016/j.ab.2008.12.024.
27. Klumpp K, Kalayanov G, Ma H, Le Pogam S, Leveque V, Jiang WR, Inocencio N, De WA, Rajyaguru S, Tai E, Chanda S, Irwin MR, Sund C, Winqist A, Maltseva T, Eriksson S, Usova E, Smith M, Alker A, Najera I, Cammack N, Martin JA, Johansson NG, Smith DB. 2008. 2′-Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J. Biol. Chem. 283:2167-2175. http://dx.doi.org/10.1074/jbc.M708929200.
28. Pierra C, Benzaria S, Amador A, Moussa A, Mathieu S, Storer R, Gosselin G. 2005. NM 283, an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids 24:767-770. http://dx.doi.org/10.1081/NCN-200060112. (Pubitemid 41440690)
29. Bressanelli S, Tomei L, Rey FA, De Francesco R. 2002. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76:3482-3492. http://dx.doi.org/10.1128/JVI.76.7.3482-3492.2002. (Pubitemid 34224549)
30. Ferrer-Orta C, Arias A, Perez-Luque R, Escarmis C, Domingo E, Verdaguer N. 2004. Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J. Biol. Chem. 279:47212-47221. http://dx.doi.org/10.1074/jbc.M405465200. (Pubitemid 39518378)
31. Gong P, Peersen OB. 2010. Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 107:22505-22510. http://dx.doi.org/10.1073/pnas.1007626107.
32. Zamyatkin DF, Parra F, Alonso JM, Harki DA, Peterson BR, Grochulski P, Ng KK. 2008. Structural insights into mechanisms of catalysis and inhibition in Norwalk virus polymerase. J. Biol. Chem. 283:7705-7712. http://dx.doi.org/10. 1074/jbc.M709563200.
33. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PLoS One 8:e68347. http://dx.doi.org/10.1371/journal.pone.0068347.
34. Stuyver LJ, McBrayer TR, Whitaker T, Tharnish PM, Ramesh M, Lostia S, Cartee L, Shi J, Hobbs A, Schinazi RF, Watanabe KA, Otto MJ. 2004. Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2′-deoxy-2′-fluorocytidine. Antimicrob. Agents Chemother. 48:651-654. http://dx.doi.org/10.1128/AAC.48.2.651-654.2004. (Pubitemid 38141737)
35. Richardson FC, Kuchta RD, Mazurkiewicz A, Richardson KA. 2000. Polymerization of 2′-fluoro- and 2′-O-methyl-dNTPs by human DNA polymerase alpha, polymerase gamma, and primase. Biochem. Pharmacol. 59:1045-1052. http://dx.doi.org/10.1016/S0006-2952(99)00414-1. (Pubitemid 30110496)
36. Tisdale M, Ellis M, Klumpp K, Court S, Ford M. 1995. Inhibition of influenza virus transcription by 2′-deoxy-2′-fluoroguanosine. Antimicrob. Agents Chemother. 39:2454-2458. http://dx.doi.org/10.1128/AAC.39.11. 2454.
37. Clark JL, Hollecker L, Mason JC, Stuyver LJ, Tharnish PM, Lostia S, McBrayer TR, Schinazi RF, Watanabe KA, Otto MJ, Furman PA, Stec WJ, Patterson SE, Pankiewicz KW. 2005. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 48:5504-5508. http://dx.doi.org/10. 1021/jm0502788. (Pubitemid 41209247)